natgillin/translations-raw huggingface dataset:
The method of claim R, wherein the vials are made from a borosilicate glass. The method of claim 7 or claim 8 or claim 9, wherein the adjuvant is a bulk adjuvant and, if the adjuvant has an acceptable squalene content, the method comprises extracting unit doses from the bulk adjuvant for packaging as kit components. 
Postupak prema patentnom zahtjevu 7 ili patentnom zahtjevu 8 ili patentnom zahtjevu 9, naznačen time, da adjuvans jest adjuvans u masi i, ako adjuvans ima prihvatljivi sadržaj skvalena, postupak sadrži ekstrahiranje jediničnih doza iz adjuvansa u masi kao komponenti za pakiranje kompleta.
simultaneously heating and pressing the stack of sheets to fuse points of contact between the nanofibres of adjacent sheets, and 
istovremenog zagrijavanja i prešanja snopa listova radi spajanja kontaktnih točaka između nanovlakana susjednih listova, i
Rodent Diabetes Models 
Modeli dijabetesa glodavaca
CHO-CB-1 cells were grown in 96 well plates to near confluence. 
CHO-CB-1 stanice uzgojene su u velikoj gustoći u 96 izvornih ploča.
The method of claim 11, wherein the chemotherapy treatment is a taxane. 
Polipeptid za uporabu prema zahtjevu 5, pri čemu je kemoterapijski tretman taksan.
Composed element according to any of the preceding claims, characterized in that the tongue (13) is situated at a distal end of the panel-shaped element (2), whereas the groove (14) is situated at a side wall of the panel-shaped element (3). 
Složeni element u skladu s bilo kojim od prethodnih patentnih zahtjeva, karakteriziran na način da je element zaključavanja (16) u žlijebu (14) smješten potpuno u materijalu odgovarajućeg vanjskog sloja (137).
Use of a combination as defined in any one of claims 1 to 8 in the manufacture of a medicament for use in the treatment of a disorder mediated by inappropriate Pl3-kinase activity. 
Upotreba spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 11, ili njegove farmaceutski prihvatljive soli, naznačena time što je spoj namijenjen proizvodnji medikamenta namijenjenog upotrebi u liječenju poremećaja uzrokovanog neodgovarajućom aktivnošću PI3-kinaze.
Provided is at least one chemical entity chosen from compounds of Formula I and compounds of Formula II: and pharmaceutically acceptable salts thereof, wherein is selected from the group consisting of hydrogen, bromo, chloro, fluoro, methyl, ethyl, propyl, hexenyl, butenyl, propenyl, vinyl, ethynyl, methoxy, ethoxy, methylsulfanyl, dimethylamino, and methyl substituted with up to three fluoro groups; 
Formula I Formula II 1 farmaceutski prihvatljive soli od njih, pri čemu R, je izabran od vodika, broma, klora, fluora, metila, etila, n-propila, izopropila, dimetilamina, izobuten-1-il, (Z)- propen-1-il, (E)-propen-1-il, propen-2-il, vinila, etinila, metoksi, etoksi, metilsulfanila, i trifluorometila;
A kit comprising at least one of: i) a polynucleotide encoding the protein according to embodiment 20 or embodiment 21 or ii) a protein according to embodiment 20 or embodiment 21. 
Komplet koji sadrži najmanje jedno od: 1) polinukleotida koji kodira protein prema patentnom zahtjevu 6 ili patentnom zahtjevu 7 ili 11) protein prema patentnom zahtjevu 6 ili patentnom zahtjevu 7.
In one embodiment, the compositions comprise, in addition to components A) to F) or instead of E) and/or F), also G) 0.01% to 10% by weight, preferably 0.1% to 5% by weight, more preferably 0.5% to 3.5% by weight, based in each case on the overall composition, of at least one laser absorber selected from the group of antimony trioxide, tin oxide, tin orthophosphate, barium titanate, aluminium oxide, copper hydroxyphosphate, copper orthophosphate, potassium copper diphosphate, copper hydroxide, antimony tin oxide, bismuth trioxide and anthraquinone, in which case the levels of the other components are reduced to such an extent that the sum total of all the percentages by weight is always 100. 
Pripravci prema bilo kojem od zahtjeva 1 do 4, naznačeni time da oni sadrže, pored komponenata A) do F) ili umjesto E) i/ili F), također G) 0.01 % do 10 masenih %, bazirano na ukupnom pripravku, barem jednog laserskog apsorbera odabranog iz skupine koju čine antimon trioksid, kositar oksid, kositar ortofosfat, barijev titanat, aluminijev oksid, bakar hidroksifosfat, bakar ortofosfat, kalijev bakrov difosfat, bakrov hidroksid, antimon kositar oksid, bizmut trioksid 1 antrakinon, u kojem su slučaju razine drugih komponenata smanjene na takvu razinu da je ukupan zbroj svih masenih postotaka uvijek 100.
alternatively, R11 and R12, together with the carbon atoms to which they are attached, combine to form a 5 to 6-membered carbocyclic ring or a 5 to 6-membered heterocyclic ring comprising: carbon atoms and 1-3 heteroatoms selected from N, NRe, O, and S; 
alternativno, R11 i R12, zajedno sa atomima ugljika za koje su vezani, kombiniraju se tako da formiraju 5- do 6-člani karbociklični prsten ili 5- do 6-člani heterociklični prsten koji sadrži: atome ugljika i 1-3 heteroatoma izabrana od N, NRe, O i S;
Thus, according to another aspect the invention provides a pharmaceutical composition, wherein at least one peptide includes non-peptide bonds. 
Peptid u skladu s patentnim zahtjevom 1 ili 2, pri čemu navedeni peptid uključuje nepeptidne veze.
Also described herein is a synthetic process for the preparation of novel tetrazoles of Formula (I) . 
Ovdje su također opisani postupci sinteze za pripremu novih tetrazola Formule (I).
In one embodiment the disclosure provides a compound of formula: 
Spoj iz patentnog zahtjeva 1 koji je spoj formule: aa
BACKGROUND OF THE INVENTION AND STATE OF THE RELATED ART 
Pozadina izuma i stanje odgovarajućeg područja tehnike
mg microcrystalline cellulose 
manitol i mikrokristalnu celulozu i
The use according to claim 11, wherein said melphalan flufenamide hydrochloride (J1) is dissolved in ethanol prior to subjecting said melphalan flufenamide hydrochloride (J1) to said sucrose. 
Uporaba u skladu s patentnim zahtjevom 11, naznačena time, da se spomenuti melfalan flufenamid hidroklorid (J1) otopi u etanolu prije izlaganja spomenutog melfalan flufenamid hidroklorida (11) djelovanju navedene saharoze.
R2b and R2c are independently selected from the group consisting of hydrogen, chloro, fluoro, methyl, trifluoromethyl, cyano, methoxy, and N(CH3)2; n is selected from the group consisting of 0 and 1; and R3 is independently selected from the group consisting of fluoro, chloro, bromo, methyl, trifluoromethyl, cyano, methoxy, and N(CH3)2. 
"E LA Spoj ili sol prema zahtjevu 1, naznačen time, da je m odabran iz skupine koju čine 01 1; R» i RC su neovisno odabrane iz skupine koju čine vodik, kloro, fluoro, metil, trifluorometil, cijano, metoksi, i N(CHs)»; n je odabran iz skupine koju čine 01 1; 1
A compound for use according to claim 1 which is N-pyridin-2-yl-N'-thiophen-2-ylmethylene-hydrazine, or a pharmaceutically acceptable salt, ester or solvate thereof. 
Spoj za uporabu sukladno bilo kod od patentnih zahtjeva 1 i 2 naznačen time da je u obliku farmaceutski prihvatljive soli, estera ili solvata.
The process according to claim 1, characterized in that the at least one mineral material is selected from the group comprising natural calcium carbonate (GCC) such as marble, chalk, limestone; precipitated calcium carbonate (PCC) such as aragonitic PCC, vateritic PCC and/or calcitic PCC, especially prismatic, rhombohedral or scalenohedral PCC; surface modified calcium carbonate; dolomite; talc; bentonite; clay; magnesite; satin white; sepiolite, huntite, diatomite; silicates; and mixtures thereof. 
Postupak prema zahtjevu 1, naznačen time da je najmanje jedan mineralni materijal odabran iz skupine koja sadrži prirodni kalcijev karbonat (GCC) kao što je mramor, kreda, vapnenac; nataloženi kalcijev karbonat (PCC) kao što je aragonitni PCC, vateritni PCC iili kalcini PCC, naročito prizmatični, tomboedarski ili skalenoedarski PCC; površinski modificirani kalcijev karbonat; dolomit; talk; bentonit; glina; magnezit, svileno bijeli; sepiolit, huntit, dijatomit; silikati; i njihove mješavine.
The method of claim 1, wherein the composition comprises about 0.1-40 mg/ml GCB, about 0.001-10% cysteine, about 1-40% sucrose, at a pH of about 5.5-6.0, and wherein the level of dissolved O2 is less than about 10%. 
Farmaceutska kompozicija prema zahtjevu 24, pri čemu kompozicija sadrži 0,1-40 mg/ml GCB, 0,001-10 % cisteina, 1-40 % saharoze, pH 5,5-6,0, i pri čemu je nivo otopljenog Oz manji od oko 10 %.
Wet granulation is a standard process in pharmaceutical manufacturing. 
Vlažna granulacija je standardni postupak u farmaceutskoj proizvodnji.
Pyridine2 represents wherein the asterisks mark the bond with which the Pyridine2 ring is bound to A; 
Piridin2predstavlja [image] [image], ili [image], gdje zvjezdice označavaju vezu kojom je prsten Piridin2vezan na A;
According to another beneficial embodiment of the invention, the vortex generator pair and the airfoil surface form a solid body without voids or air inclusions. 
Lopatica vjetroturbine prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time da je navedeni vrtložni generator pričvršćen na površinu propelera i navedene osnovne podloge, navedena peraja 1 navedena površina formiraju čvrsto tijelo bez utjecaja zraka.
In certain embodiments, the present invention is directed to a solid oral extended release pharmaceutical dosage form comprising an extended release matrix formulation, the extended release matrix formulation comprising a composition comprising at least: 
Farmaceutski oblik doziranja s produljenim otpuštanjem u krutom obliku prema zahtjevu 1, 2 ili 3, naznačen time da je formulacija matrice s produljenim otpuštanjem otporna na rad od barem oko 0.06 J bez pucanja.
wherein the dominant-negative DA polypeptide comprises an amino acid sequence having at least 50% sequence identity to SEQ ID NO: 1, said amino acid sequence comprising a UIM1 domain, a UIM2 domain, a LIM domain, and a mutation of R to K at a position equivalent to position 358 of SEQ ID NO: 1, and 
i obuhvaća aminokiselinsku sekvencu koja ima najmanje 50% o jeni teta sekvence odi SEQ ID NO:1, gdije navedena aminokiselinska sekvenca obuhvaća UiM|-domenu, UIMZ-domenu, LIM-domenu i mutaciju od R na K, na poziciji koja je ekvivalentna poziciji 358 od SEQ ID NO:1.
a number of data elements stored in said storage locations is transmitted to said concentrator (C), said number being determined by said concentrator (C). 
- broj podatkovnih elemenata pohranjenih na navedenim lokacijama za pohranu se prenosi u sabirnik (C) koji broj određuje sabirnik (C).
The antibody according to claim 6, whereby the amount of fucose within said sugar chain is between 5% and 65%. 
Protutijelo prema zahtjevu 6, naznačeno time, da je količina fukoze unutar spomenutog šećernog lanca u rasponu od 5% do 65%.
an amine, optionally in the presence of an additive selecetd from an alkaline earth metal halide; 
- < amina, po izboru u prisutsvu aditiva odabranog od zemnoalkalnih metala halida;
and endo isomers: epimerizing said trans-[5,6]-ring-junction in Compound 29 by treating said first mixture with a first base to produce a second mixture comprising cis-[5,6]-ring-junction-nitro-a isomer and cis-[5,6]-ring-junction-nitro-B isomer of Compound 30: and, 
(b) epimerizacije navedene zrans-[5,6]-veze u prstenu u Spoju 29 obradom navedene prve smjese prvom bazom kako bi se dobilo drugu smjesu, koju čini nitro-a izomer s cis-[5,6]-vezom u prstenu i nitro-f izomer s cis- [5,6]-vezom u prstenu Spoja 30: cis
measurement in the pharmaceutical formulation obtained in step a) of the concentration of free macrocyclic chelate Cch l and/or of free lanthanide Clan l; 
mjerenje u farmaceutskoj formulaciji dobivenoj u koraku b) koncentracije slobodnog lantanida Clan 1; a koncentracija slobodnog makrocikličkog kelata Cch1 jednaka je 0;
The use of epothilone D according to claim 6, wherein the dose of epothilone D to be administered intravenously over a one month cycle, regardless of schedule, is in the range between 0.1 - 3 mg/m2. 
Uporaba epotilona D u skladu s patentnim zahtjevom 6, pri čemu je doza epotilona D za intravensko davanje tijekom jednomjesečnog ciklusa, bez obzira na raspored, u rasponu između 0.1 - 3 mg/m2.
The groove structures ultimately form the flow channels of the nozzle arrangements, which preferably have dimensions in the micrometre range. 
Brazdaste strukture konačno tvore protočne kanale naprave s mlaznicom, koja ima dimenzije ponajprije u mikrometarskom području.
When the modified saccharide contains an amino group, it may be derived from an anomeric hydroxyl group. Amino groups are readily accessible from anomeric hydroxyl groups by reductive amination (using, for example, NaBH3CN/NH4Cl). Similarly, in other preferred embodiments, there is at least one monosaccharide unit of the modified capsular saccharide where two vicinal hydroxyl groups of the corresponding native capsular saccharide do not comprise blocking groups. 
Modificirani saharid iz kapsule u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što: a) modificirani saharid sadrži terminalnu anomernu hidroksilnu skupinu ili amino skupinu izvedenu iz terminalne anomerne hidroksilne skupine; ili b) u modificiranom saharidu kapsule se nalazi najmanje jedna monosaharidna jedinica u kojoj dvije vicinalne hidroksilne skupine u odgovarajućem nativnom saharidu kapsule ne sadrže blokirajuće skupine.
In one embodiment, the additional agent is selected from a mucolytic agent, bronchodialator, an anti-biotic, an anti-infective agent, an anti-inflammatory agent, a CFTR modulator other than a compound of the present invention, or a nutritional agent. 
Farmaceutski pripravak koji sadrži spoj N-(5-hidroksi-2,4-diterc-butil-fenil)-4-okso-1H-kinolin-3-karboksamid ili njegovu farmaceutski prihvatljivu sol, pri čemu navedeni pripravak nadalje sadrži: a) farmaceutski prihvatljiv nosač ili adjuvant; i b) dodatno sredstvo odabrano od mukolitičkog sredstva, bronhodilatatora, antibiotika, antiinfektivnog sredstva, protuupalnog sredstva, modulatora cistično fibroznog transmembranskog receptora (CFTR) ili prehrambenog sredstva.
A 100mL RBF was equipped with a magnetic stir bar, a nitrogen purge, and a condenser, and was wrapped with aluminum foil. 
RBF od 100 mL je bila opremljena s magnetskom šipkom za miješanje, dušičnim pročišćivačem, i kondenzatorom, i bila je omotana aluminijskom folijom.
The process according to claim 9, wherein the steroidal molecule is selected from the group consisting of estradiol and esters thereof, ethinyl estradiol, conjugated estrogens, testosterone and esters thereof, cyproterone, drospirenone, etonogestrel, desogestrel, gestodene, levonorgestrel, norethisterones, norgestimate, norethindrone, norethindrone acetate, norethynodrel, norgestimate, norgestrel, medrogestone, medroxyprogesterone acetate, progesterone, spironolactones, eplerenone, canrenoate, canrenone, dicirenone, mexrenoate, prorenoate, epostane, mespirenone, oxprenoate, spirorenone, spiroxasone, prorenone, asoprisnil, beclomethasone dipropionate, betamethasone, betamethasone valerate, budesonide, clobetasol propionate, clobetasone butyrate, cortisone acetate, dexamethasone, fludrocortisone acetate, prednisolone, prednisone, alfacalcidol, calcifediol, calciferol and calcitriol. 
Postupak prema zahtjevima 6 ili 7, naznačen time, da je steroidna molekula izabrana iz grupe koja se sastoji od estradiola i njegovih estera, etinil estradiola, konjugiranih estrogena, testosterona i njegovih estera, ciproterona, drospirenona, etonogestrela, desogestrela, gestodena, levonorgestrela, noretisterona, norgestimata, noretindrona, noretindron acetata, noretinodrela, norgestimata, norgestrela, medrogestona, medroksiprogesteron acetata, progesterona, spironolaktona, eplerenona, kanrenoata, kanrenona, dicirenona, meksrenoata, prorenoata, epostena, mespirenona, oksprenoata, spirorenona, spiroksanona, prorenona, azoprisnila, becimetazon dipropionata, betametazona, betametazon valerata, budesonida, klobetazol propionata, klobetazon butirata, kortizon acetata, deksametazona, fludrokortizon acetata, prednizolona, prednizona, alfakalcidola, kalcifediola, kalciferola ili kalcitriola.
The syringe of claim 12, wherein the at least one first lug has at least one hollow section defined by the plurality of separate surfaces of the top surface and projecting radially inward from the top surface. 
Å trcaljka prema zahtjevu 10, naznačena time da barem jedna prva ušica (34) ima barem jedan šuplji dio definiran s mnoštvom odvojenih površina gornje površine (46) i izbočen radijalno prema unutra od gornje površine (46).
In an illustrative application of the invention, 
Datum objave europske prijave patenta:
In a further embodiment, compounds of the present invention and combination therapies are administered in conjunction with exercise and/or a sensible diet. 
U slijedećem obliku, spojevi prikazanog izuma i kombinacije terapija su primjenjeni uz vježbanje i/ili dijetu.
the inorganic filler is selected from a precipitated calcium carbonate, a barite, blanc fixe, talcum, pyrophyllite, a chlorite, hornblende and mica, and 
Obložni materijal prema zahtjevu 6, naznačen time, da su punila odabrana iz skupine koju čine nataloženi kalcijev karbonat, barit, blank fiks, talk, pirofilit, klorit, hornblende i liskun.
In another embodiment the preparation is in form for oral intake, preferably in form of pastilles, tablets, gums, lozenges, powders or drinking solutions. 
Upotreba temeljem bilo kojeg od zahtjeva 1 do 9, naznačena time što je preparat u obliku za oralni unos, poželjno u obliku pastila, tableta, guma, pastila, prašaka ili otopina za piće.
A method for the treatment of respiratory distress syndrome (RDS) in a prematurely born baby, comprising administering an effective amount of a reconstituted surfactant according to claim 1 to said prematurely born baby. 
Rekonstituirani surfakant prema bilo kojem od patentnih zahtjeva 1 do 13, naznačen time da se koristi za liječenje i profilaksu respiratornog distresnog sindroma kod prerano rođene djece ili za liječenje i profilaksu drugih bolesti povezanih s nedostatkom surfakanta ili disfunkcijom.
The weight content of the polymerizable resin base in the composite material is typically in the range of 5-95%, or 10-90%, e.g. 
Masa sadržaja baze za smolu koja polimerizira u kompozitnom materijalu je u rasponu od 5-95% ili 10-90%, npr.
The aptamer of any one of claims 1 to 4, wherein the aptamer comprises at least three of said base-modified nucleotides. 
Aptamer prema zahtjevu 1 ili 2, naznačen time, da aptamer obuhvaća najmanje tri od navedenih uridin-nukleotida modificiranih s bazom.
European Patent Specification no. 
Broj europske prijave patenta:
Polymorph Form II of 7-(dimethoxy-methyl)camptothecin which undergoes degradation starting from the temperature of about 160° C., wherein said polymorph shows an X-ray powder diffraction pattern having the following characteristic peaks expressed in degrees 2Θ±0.2 
Polimorfni Oblik II u skladu s patentnim zahtjevom 1, naznačen time što pokazuje uzorak difrakcije rendgenskih zraka na prahu koji imaju sljedeći karakteristične signale, izražene u stupnjevima 26 + 0,2
An isolated binding polypeptide comprising an Fc domain with altered glycosylation, wherein the Fc domain comprises: an asparagine residue at amino acid position 298, according to EU numbering; and a serine or threonine residue at amino acid position 300, according to EU numbering, and wherein the binding polypeptide exhibits reduced effector function due to said altered glycosylation. 
Izolirano protutijelo koje sadrži ljudsku IgG1 Fc domenu, naznačeno time da ljudska IgG1 Fc domena sadrži glikozilirani asparaginski ostatak na položaju aminokiseline 298, u skladu s EU označavanjem; i serinski ili treoninski ostatak na položaju aminokiseline 300, u skladu s EU označavanjem.
is selected from the group consisting of isopropenyl, Z-2-propen-3-yl and (+)-vinyl; is OH; 
R* je izabran iz grupe koja se sastoji od izopropenil, Z-2-propen-3-il i (-*-)-vinil;
a feed opening in the side wall of the furnace chamber to feed batch material from the bottom of the hopper to the pool of glass melt below the melt level; 
utovarni otvor (87) u bočnoj stijenci komore za taljenje u peći, u svrhu utovarivanja smjese materijala s dna lijevka do bazena s rastaljenim staklom ispod razine taljenja;
In the sweetener composition according to the invention, the problem regarding replacing the bulking and texturing function of sugar can only partially be solved by the addition of maltitol and isomalt. 
U sastavini sladila koja je predmetom ovog izuma, problem s nadomještanjem šećerove funkcije povećavanja mase i teksture može sc samo djelomice premostiti dodavanjem maltitola i izomalta.
and wherein any atom of the ring structure of the 5-7 membered carbocycle or heterocycle is optionally substituted in one or more positions with R9. 
[image] [image] te je pritom bilo koji atom iz prstenaste strukture od 5-7-članog karbocikla ili heterocikla, opcionalno supstituiran na jednoj ili više pozicija s R9;
the second fusion protein is encoded by SEQ ID NO:4 or a nucleic acid that is at least 95% identical to SEQ ID NO:4. 
(b) drugi fuzijski protein je kodiran sa SEQ ID NO:4 ili nukleinskom kiselinom koja je najmanje 95% identična sa SEQ ID NO:4.
The method according to claim 1 or 2, wherein the p-toluenesulfonic acid or p-toluenesulfonic acid monohydrate of step (a) is at 0.8 molar equivalent or more and less than 1.0 molar equivalent with respect to the compound represented by formula (B). 
Postupak prema zahtjevu 1 ili 2, pri čemu the p-toluensulfonska kiselina ili monohidrat p-toluensulfonske kiseline iz koraka (a) je 0.8 molarni ekvivalent ili više te manje od 1.0 molarni ekvivalent u odnosu na spoj predstavljen formulom (B).
Aerosol container according to Claim-3, wherein the adhesive tag is dimensioned such that areas of the tag surround the spacer and the aerosol container. 
Spremnik aerosola u skladu sa zahtjevom 3, naznačen time, da je ljepljiva naljepnica dimenzionirana tako da područje naljepnice okružuje umetak i spremnik aerosola.
A valve gearbox as claimed in claim 12, wherein said valve monitoring sensor, said gate position sensor and said lid sensor are reed switches that co-operate with respective permanent magnets, there being a valve monitoring sensor permanent magnet carried in a bolt used for bolting said mounting to said mounting flange, a gate position sensor permanent magnet carried by said arm, and a lid position sensor permanent magnet carried by said lid. 
Sklop za upravljanje ventilom s mehaničkim prijenosom prema Zahtjevu 6, gdje su navedeni senzor (83) za nadzor nad ventilom, navedeni senzor (85) položaja vrata ventila i navedeni senzor (91) poklopca Reedovi prekidači koji surađuju s odgovarajućim permanentnim magnetima, pri čemu je permanentni magnet senzora za nadzor nad ventilom nošen u zavrtnju iskorištenom za fiksiranje navedenog elementa za fiksiranje za navedenu montažnu prirubnicu, pri čemu je permanentni magnet senzora položaja vrata ventila nošen od strane navedenog kraka i pri čemu je permanentni magnet senzora položaja poklopca nošen od strane navedenog poklopca.
The membrane materials used are preferably but not exclusively polymers. Useful polymers in the separation-active layer are more preferably polyimides, polyamides, polysulfones, cellulose acetates and derivatives, polyphenylene oxides, polysiloxanes, polymers with intrinsic microporosity, mixed matrix membranes, facilitated transport membranes, polyethylene oxides, polypropylene oxides, carbon membranes or zeolites, or mixtures thereof. 
Postupak prema bilo kojem od zahtjeva 1 do 8, naznačen time da materijali koji se koriste za separacijski membranski aktivni sloj su amorfni ili polu-kristalni polimeri, na primjer ali ne isključivo poliimidi, poliamidi, polisulfoni, celuloza acetati i derivati, polifenilen oksidi, polisiloksani, polimeri s intrinzičnom mikroporoznosti, membrana s miješanom matricom, membrane s olakšanim transportom, polietilen oksidi, polipropilen oksidi ili njihove smjese.
A nucleic acid molecule, having a nucleotide sequence of SEQ ID NO. 2, which is operably linked to a gene encoding diaminopimelate dehydrogenase. 
Molekula nukleinske kiseline, koja ima nukleotidnu sekvencu prema identifikacijskom broju (SEQ ID NO.)